Mupirocin Calcium

Sold as Bactroban. Every FDA application for this active ingredient: 2 branded and 7 generic.

As of Nov 15, 2026, FDA lists 9 applications for Mupirocin Calcium (sold as Bactroban), first approved Sep 18, 1995, with 0 new uses approved and 0 published complete response letters.

First approved: Sep 18, 1995
Applications: 9
New uses approved: 0
Complete response letters: 0

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

MUPIROCIN 2% CREAM: $0.852 per GMGeneric · -16% in a year
MUPIROCIN 2% OINTMENT: $0.145 per GMGeneric · +4% in a year

Clinical Trials

12 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After MastectomyBreast Cancer, Breast Cancer Female · Memorial Sloan Kettering Cancer Center	Phase 2	Recruiting	Nov 5, 2026
Prophylactic Antibiotic Duration in Head and Neck Cancer Surgery (PROTECT-HN Trial)Surgical Wound Infection, Head and Neck Neoplasms · AC Camargo Cancer Center	Phase 3	Recruiting	Oct 1, 2026
Silver-Impregnated Dressings for Catheter Exit-Site and Tunnel Infections in Peritoneal Dialysis PatientsPeritoneal Dialysis Catheter Exit Site Infection, Peritoneal Dialysis Catheter Tunnel Infection · Singapore General Hospital	Not applicable	Not yet recruiting	Jun 11, 2026
Thermosensitive Gel Nasal Spray With Stem Cell Exosomes, Mupirocin, and DNase I for Chronic SinusitisChronic Rhinosinusitis With Nasal Polyps · The First Affiliated Hospital of Xinxiang Medical College	Early phase 1	Not yet recruiting	Jun 9, 2026
Staph Nasal Decolonization to Improve Function and FeedingRadiation Mucositis, Staphylococcal Aureus Infection · David Palma	Phase 2	Not yet recruiting	Apr 13, 2026
The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to HealSurgical Wound Infection · Cooper Norcross Health	Phase 3	Recruiting	Aug 26, 2025
The Impact of Pharmaceutical Care on the Infection Control Measures Among Hemodialytic PatientsInfection, Hemodialysis Patients · University of Sulaimani	Not applicable	Active, not recruiting	May 13, 2025
Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin TreatmentStaphylococcal Aureus Infection, Microbial Colonization · Johns Hopkins University	Phase 1	Recruiting	Feb 3, 2025

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Sep 18, 1995	BactrobanNDA 50703 · New active ingredient	Glaxosmithkline	12	Discontinued
Dec 11, 1997	BactrobanNDA 50746 · New dosage form	Glaxosmithkline	15	Discontinued
Jan 24, 2013	MupirocinANDA 201587	Glenmark Pharms	7	Marketed
Apr 27, 2020	MupirocinANDA 207116	Sun Pharma Canada	0	Marketed
Aug 31, 2021	MupirocinANDA 213076	Encube	0	Marketed
Nov 16, 2021	MupirocinANDA 213053	Alembic	0	Marketed
Aug 3, 2022	MupirocinANDA 212465	Padagis Israel	0	Discontinued
Nov 15, 2022	MupirocinANDA 214811	Amneal	0	Marketed
Sep 29, 2026	Mupirocin CalciumANDA 218361	Zydus Lifesciences	0	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA